These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34234465)

  • 1. The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and
    Anekpuritanang T; Uataya M; Claimon A; Laokulrath N; Pongsapich W; Pithuksurachai P
    Onco Targets Ther; 2021; 14():3959-3969. PubMed ID: 34234465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma.
    Dong H; Shen WZ; Yan YJ; Yi JL; Zhang L
    J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):77-81. PubMed ID: 26838744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells.
    Zhang H; Chen D
    Thyroid Res; 2018; 11():13. PubMed ID: 30337961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The correlation of sodium iodide symporter and BRAF(V600E) mutation in classical variant papillary thyroid carcinoma.
    Yazgan A; Yıldırım N; Gözalan A; Gümüştaş S; Kılıçarslan A; Balci S; Aydın C; Ersoy R; Cakir B; Güler G
    Ann Diagn Pathol; 2016 Jun; 22():58-62. PubMed ID: 27180062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
    Gao WL; Wie LL; Chao YG; Wie L; Song TL
    Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NADPH Oxidase NOX4 Is a Critical Mediator of BRAF
    Azouzi N; Cailloux J; Cazarin JM; Knauf JA; Cracchiolo J; Al Ghuzlan A; Hartl D; Polak M; Carré A; El Mzibri M; Filali-Maltouf A; Al Bouzidi A; Schlumberger M; Fagin JA; Ameziane-El-Hassani R; Dupuy C
    Antioxid Redox Signal; 2017 May; 26(15):864-877. PubMed ID: 27401113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 8. Do BRAFV600E mutation and sodium-iodide symporter expression affect the response to radioactive iodine therapy in patients with papillary thyroid carcinoma?
    Makboul R; Mostafa NM; El-Deek HEM; Aboulhagag NA; Shehata MR; Abdelhafez YG
    Nucl Med Commun; 2020 May; 41(5):416-425. PubMed ID: 32168263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer.
    Zhang Z; Liu D; Murugan AK; Liu Z; Xing M
    Endocr Relat Cancer; 2014 Apr; 21(2):161-73. PubMed ID: 24243688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
    Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
    Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring
    Fu H; Cheng L; Jin Y; Cheng L; Liu M; Chen L
    Mol Ther Oncolytics; 2019 Mar; 12():235-245. PubMed ID: 30847387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Inverse Agonist of Estrogen-Related Receptor Gamma, GSK5182, Enhances Na
    Singh TD; Lee JE; Son KH; Lee BR; Kim SK; Gulwani D; Sarangthem V; Jeon YH
    Cells; 2023 Feb; 12(3):. PubMed ID: 36766812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
    Durante C; Puxeddu E; Ferretti E; Morisi R; Moretti S; Bruno R; Barbi F; Avenia N; Scipioni A; Verrienti A; Tosi E; Cavaliere A; Gulino A; Filetti S; Russo D
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2840-3. PubMed ID: 17488796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.
    Durante C; Tallini G; Puxeddu E; Sponziello M; Moretti S; Ligorio C; Cavaliere A; Rhoden KJ; Verrienti A; Maranghi M; Giacomelli L; Russo D; Filetti S
    Eur J Endocrinol; 2011 Sep; 165(3):455-63. PubMed ID: 21653734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction.
    Paja Fano M; Ugalde Olano A; Fuertes Thomas E; Oleaga Alday A
    Endocrinol Diabetes Nutr; 2017 Feb; 64(2):75-81. PubMed ID: 28440781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
    Jafri S; Yaqub A
    Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.
    Riesco-Eizaguirre G; Gutiérrez-Martínez P; García-Cabezas MA; Nistal M; Santisteban P
    Endocr Relat Cancer; 2006 Mar; 13(1):257-69. PubMed ID: 16601293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of the Expression of BRAF V600E Mutation With Various Phenotypic Expressions of Thyroid Neoplasms.
    Harikrishnan V; Kumari S; Ramkumar S; Sankaran R; Ramalingam S; Sairam T
    Cureus; 2021 Jun; 13(6):e16048. PubMed ID: 34345541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer.
    Colombo C; Minna E; Gargiuli C; Muzza M; Dugo M; De Cecco L; Pogliaghi G; Tosi D; Bulfamante G; Greco A; Fugazzola L; Borrello MG
    J Exp Clin Cancer Res; 2020 Nov; 39(1):245. PubMed ID: 33198784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.